Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 0.52 |
| ▸ | CA2 | P00918 | 16/20 | 0.52 |
| ▸ | CA9 | Q16790 | 14/20 | 0.52 |
| ▸ | CA12 | O43570 | 8/20 | 0.52 |
| ▸ | CA7 | P43166 | 6/20 | 0.52 |
| ▸ | CA6 | P23280 | 5/20 | 0.52 |
| ▸ | CA5A | P35218 | 5/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.52 |
| ▸ | CA4 | P22748 | 5/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552228 | 0.82 | SNCA (0.38) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5898261 | 0.82 | PTGS2 (0.40) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2005577 | 0.79 | CA2 (0.56) | CA1CA2CA9CA12CA7 | |
| SCHEMBL3949466 | 0.78 | CA2 (0.53) | CA1CA2CA9CA12CA7 | |
| SCHEMBL23851032 | 0.78 | CA2 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10750259 | 0.78 | CA1 (0.42) | CA1CA2CA9CA12CA7 | |
| SCHEMBL15787787 | 0.75 | CA2 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL501769 | 0.73 | PGK1 (0.48) | KDM4EALDH1A1 | |
| SCHEMBL92965 | 0.73 | ACHE (0.48) | KDM4EALDH1A1 | |
| SCHEMBL11176657 | 0.73 | TPMT (0.59) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| CN-101374818-A | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981856-A2 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | EPHB4, EPHB1, EPHB3 | CA1 4634/4885CA2 3427/4885CA9 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.